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Abstract 
 
 Creatine (Cr) was initially discovered in the 1830s by a Frenchman named 
Chevreul. In subsequent years, it was discovered that creatine was utilized by the 
musculatory system, which fueled research on its overall use as a metabolite in the 
human body. Investigation into the role of this chemical in the human body led to its 
current use as a sports supplement and potential treatment option for individuals with 
musculatory disorders such as Parkinson’s and Huntington’s. With creatine’s increased 
use as a sports supplement there is also a strong interest in its long term effects, as well as 
its potential as a treatment option. There is need for further investigation as well as a 
means for dosage determination, and a method that will allow for accurate concentration 
determination. The current methods used to determine creatine concentration are time 
consuming and complicated analytical methods such as high pressure liquid 
chromatography (HPLC) and gas chromatography-mass spectroscopy (GS-MS). A single 
reagent enzymatic assay (Cr assay) that can be used on any bench top chemistry analyzer 
for accurate and precise measurement of Cr in human serum and aqueous samples was 
developed and is summarized here. The assay can measure samples in 10 minutes, is 
linear from 0-15mg/dL of Cr, the reagent has a shelf life of 45 days refrigerated. The Cr 
assay is within 98% accuracy, run to run CV from 1.6-5.3% for clinical samples and a 
sample-to-sample CV of less than 0.5%. This assay can easily be adapted for any bench 
top chemistry analyzer that has the capability of a programmable channel, and can read 
clinical samples with accuracy, precision and reproducibility. 
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Chapter I 
Introduction 
 
 
   
 Creatine (Cr) was initially discovered in the 1830s by a French man named 
Chevreul (Hunter, 1928; Lundsgaard, E. 1930; Balsom 1994). Studies of this chemical 
have been ongoing ever since, the first of which was done in foxes by Lieberg in 1847, 
who noted that foxes killed during a fox chase had much higher concentrations of Cr than 
those killed in captivity (Hunter, 1928; Lundsgaard, E. 1930; Balsom 1994).  With the 
discovery of creatinine (crea) in urine by Heintz and Pettenkofer speculations began that 
the crea was derived by the cr stored in muscles (Hunter, 1928; Lundsgaard, E. 1930; 
Balsom 1994).  
 This eventually led to studies on cr ingestion, which showed that not all cr 
ingested could be recovered in urine, indicating that it was being utilized by the body. 
Although there have been a multitude of studies completed to investigate the metabolism 
of cr, few investigated the effect and role of cr supplementation on exercise and 
performance in humans. Only recently have these studies been gaining popularity, and 
with the gain in interest in cr, the scientific community has experienced an increased need 
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for a method to detect cr concentration in the human circulatory and musculatory systems 
that is quick and reliable. (Schilling 2001). 
Potential Beneficial Impacts of Cr 
 As the knowledge of the musculatory system and its function increases so are the 
possible treatment options for patients with muscular dysfunctions. The role of cr in the 
musculatory system has made it a key target for treatment of disorders such as 
Parkinson’s, Huntington’s disease (HD) and sclerosis (Ferrante 2000; Andrew 1993; 
Taylor 1995; Bender 2006). HD is a genetic neurodegenerative disease that has a very 
late onset of mid to late life (Ferrante 2000). Symptoms of the disease include but are not 
limited to loss of motor function, mental function and behavioral symptoms (Ferrante 
2000; Andrew 1993). Ferrante tested cr supplementation in an HD mouse model in 2000; 
the data suggested that cr could be used as a novel therapeutic agent (Ferrante 2000). 
Testing showed that cr supplementation in the HD mouse model significantly increased 
survival, slowed the development of brain atrophy, and delayed atrophy of striatal 
neurons and the formation of huntingtin-positive aggregates, therefore delaying the onset 
and severity of symptoms of HD (Ferrante 2000).  Parkinson’s disease is also a 
degenerative disorder but impacts the central nervous system, which in turn affects motor 
function (Taylor 1995).  In 2006, a randomized placebo-control study was conducted at 
the University of Munich by Bender et. al. using 60 Parkinson’s disease patients to 
determine the effects of cr supplementation on the progression of the disease symptoms 
(Bender 2006).  Although the study results did not prove promising for the motor 
function of the patient population, patients did experience an increase in positive feelings, 
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outlook and overall mood, allowing for the reduction of dopaminergic therapy dosage 
(Bender 2006). A summary of the potential benefits of Cr supplementation was published 
by Tarnopolski in 2000 which indicates clear evidence that Cr monohydrate has potential 
neuroprotective effects in animal models of Parkinson’s disease, Alzheimer’s disease, 
after ischemia and amyotrophic lateral sclerosis (Tarnopolsky 2000). These are only a 
few examples of the current research being conducted to determine a beneficial impact 
for Cr supplementation. As many researches mentioned in their publications, there is an 
increasing need for further research in the impact of Cr as a supplement (Becque 2000; 
Farquhar 2002; Yoshizumi 2004). In addition to investigation on beneficial implication of 
Cr, there is also ongoing investigation on the long-term impact of cr supplementation on 
healthy individuals (Becque 2000; Farquhar 2002; Yoshizumi 2004). 
Current Assays for Cr Detection 
 Currently, research on the effects of Cr supplementation on kidney function relies 
on more complicated analytical methods such as HPLC and GC-MS (Yoshimuzi 2004). 
In this growing research field there is a need for a method to measure cr with high 
throughput and without complicated separation techniques. Arias, et al. published a paper 
in 2006 explaining the current and very complicated procedure of Cr detection (Arias 
2006). High pressure liquid chromatography-tandem mass spectrometry (HPLC/MS) is a 
process which combines the capabilities of liquid chromatography to physically separate 
chemical compounds and the capability of mass spectrometry to detect the mass of a 
compound (Aebersold 2003; Jonsson 2004). A sample that potentially contains Cr is 
passed through a liquid chromatography column filled with adsorbent material, and 
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chemical components that are in the sample each react differently with the adsorbent 
material. The time it takes for each compound to pass through the column is different 
based on that interaction (Aebersold 2003). Each chemical passes through the column at 
different rates allowing for the separation and identification of each chemical based on 
the interaction with the adsorbent material (Aebersold 2003). A very complicated method 
that also has other limitations, such as interfering substances such as crea, and other 
metabolites such as glucose which will not allow for proper separation with Cr molecule 
and therefore will give incorrect or no results at all (Aebersold 2003).Mass spectrometry 
enables identification of amount and type of chemicals present in a solution (Schilling 
2001). This is done by separating the chemicals based on the mass to charge ratio in their 
gas-phase (Jonsson 2004). The second method described by Arias is gas chromatography 
mass spectroscopy (GS/MS). Similar to liquid chromatography, gas chromatography 
separates chemicals, but does so by vaporization, and is then combined with mass 
spectrometry to detect the presence and concentration of each chemical (Arias 2006; 
Rawson 2011). As Arias et. al. concludes, in comparing Cr to Crea ratios in patient 
samples there is a constant and proportional error and therefore the Cr to Crea ration 
should be evaluated with caution, especially when using GC/MS (Arias 2006). Finally 
BioVision (Milpitas, CA) has a colorometric/fluorometric assay kit, which uses a 
colorometric or fluorometric intensity change to detect the concentration of cr in samples 
(Rawson 2011). The assay is relatively easy to use according to the manufacturer’s 
instructions – but the reaction requires 1 hour for incubation and no separation is 
requiered. However, the assay is for research purposes only and is not traceable to 
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standard methods so it cannot be used for clinical testing. The methods currently 
available to test for cr in clinical samples are either very complicated to use such as 
GC/MS and HPLC/MS or not approved for analysis of patient samples. There is an 
increasing need for the ability to quickly analyze cr in patient samples to be able to 
evaluate cr deficiency syndroms (Arias 2006). There is also an increased need for 
evaluation of long-term cr supplementation (Yoshizumi 2004). 
Assay Requirements 
 To be able to detect an unknown concentration of a chemical, the assay must 
fulfill some basic requirements. The method of detection must be sensitive enough to 
respond to the lowest concentrations that are to be measured. The detection method must 
be accurately and easily calibrated against a known standard concentration that is within 
the range in which is to be detected, and the reaction must be linear in response to the 
concentration ranges of measurement.  For clinical sample analysis, the impact of 
biological sample matrix on accuracy and precision should be part of the critical criteria 
of the assay. This is applicable to any measurement system that is sensitive to a specific 
chemical in any background matrix. Currently to calculate accurate estimated glomerular 
filtration rate (eGFR) hospitals must have a system that can accurately measure 
concentrations of crea in either blood or plasm over a period of time from the same 
patient (Levey 1999). Therefore a hospital must have an instrument that can accurately 
measure the Crea level from a patient’s blood or serum. Instruments that are utilized for 
these purposes in hospitals are either large, slow bench top chemistry analyzers, or 
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critical care instruments which are smaller and easier with much quicker throughput. 
These instruments are capable of measuring crea using enzymatic methods via detection 
of colorimetric changes or current changes (Pamidi 2010). Pamidi explains that by taking 
advantage of the natural breakdown process of crea via enzymatic methods, one can 
develop a sensor that has the capability to detect the final breakdown product, hydrogen 
peroxide, which can be detected by a spectrophotometer or by a current detector. There 
has not been a method developed that utilizes a similar concept for the accurate detection 
of Cr in human blood.  
Proposed Enzymatic Creatine Assay from Adapting Enzymatic Creatinine Assay 
 For the measurement of crea in clinical samples, a quick assay has been 
developed utilizing creatinine amidohydrolase (creatininase), creatine amidohydrolase 
(creatinase) and sarcosine oxidase as can be seen in Figure 1 to convert crea to cr then 
creatine to urea and sarcosine. Sarcosine is then converted to formaldehyde and hydrogen 
peroxide. Hydrogen peroxide will interact with a specific dye or chromophore to give a 
colorimetric change, which can be detected by a spectrophotometer. This assay has been 
made available by several different manufacturers such as Roche, Sekisui, and Horriba. 
The available assays are two-step, two reagent assays, in which reagent one contains 
creatinase, which converts cr to sarcosine and urea. This is done to eliminate all cr 
present in the sample as it causes interference with the crea detection. Sarcosine oxidase 
is in turn needed to convert the produced sarcosine to glycine, formaldehyde and 
hydrogen peroxide. The time delay between the addition of the first and second reagent 
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allows for the degradation of hydrogen peroxide which is determined by the 
concentration of the enzymes present in the reagent. The second reagent contains 
creatininase which converts Crea to Cr and the creatinase that is still present in reagent 
one converts Cr to sarcosine and the same cascade reaction will follow until hydrogen 
peroxide is formed. The hydrogen peroxide will interact with the 4-aminoantipyrine dye 
in reagent two, which is catalyzed by horse radish peroxidase to give a color change that 
can be detected by photospectrometry. We are proposing a similar enzymatic based 
method to allow for the breakdown of Cr to hydrogen peroxide. The enzymatic method 
that we are suggesting only requires a single reagent as the Cr molecule can be directly 
converted to sarcosine by the creatinase enzyme that is in reagent one of crea assay and 
the produced sarcosine is converted to hydrogen peroxide, which will react with 4-
aminoantipyrine in the presence of horse radish peroxidase to allow for detection via uv-
vis on any photospectrometer. All chemicals can be maintained in one reagent as no time 
delay is needed.  
Having a reference material such as National Institute of Standard and Technology 
(NIST) traceable standard allows for accurate clinical assay development and is 
recommended by FDA regulations. Unlike crea, there is no NIST traceable Cr standard 
available making the assay development more challenging. As there are very limited 
testing assays currently available on the market for Cr and most of them are for 
laboratory research purposes only, there is a need for a method with quicker results, 
which can be utilized for clinical sample measurement. 
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Goals for Creatine Assay 
 Our ultimate goal is to create an accurate and convenient creatine assay, which is 
quick and easy to use. It is based on a single part reagent via enzymatic conversion of 
creatine with colorimetric end point detection of 4-aminoantipyrine at 547 nm. In contrast 
to the purchasable manual microtiter plate based assay, our assay incubation time is much 
faster so it can be fully automated by easily adapting it to any clinical chemistry analyzer 
which provides customizable assay channels.  The cr in clinical samples can be analyzed 
simultaneously with other commercially available assays like crea, glucose, lactate, etc.   
 Using a bench top chemistry analyzer, the goal is to develop a cr assay through 
optimizing assay conditions and procedures with a specific small (<300uL) sample and 
reagent volume, and an incubation time of less than 20 minutes. Methods and procedures 
will be developed for calibration standards and reagents that can measure the cr 
concentrations in clinical samples. The assay will achieve linearity of 0-15mg/dL, 
accuracy within 2%, recovery within +/- 3% from gravimetric values. In addition, 
coefficient of variation (CV), which is a standardized measure of dispersion of a 
probability distribution or frequency distribution, will be applied to analyze variability 
from samples and runs. It is defined as the ratio of the standard deviation to the mean.  
The target set for run to run is CV of less than 2% and sample to sample of 0.5%.  
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Chapter II 
Materials and Methods 
 
 
 Materials and methods utilized for the development of the enzymatic creatine 
assay include participants who provided human blood and serum samples. To measure 
the outputs of our assay instruments such as a benchtop chemistry analyze and a 
spectrophotometer were utilized. Reagents, calibration material and standard (control) 
material were developed along with parameters for specific use on bench top chemistry 
analyzers with an open channel feature. Finally data processing and statistical outputs 
were utilized to determine the success of our enzymatic creatine assay. 
Participants 
 Participants are individuals that have in some form contributed to the 
development on the cr enzymatic assay; individuals from who blood and serum were 
used are participants. For the purposes of our study human biological samples such as 
blood and serum were needed to test the capability of the enzymatic cr assay. Human 
blood and serum were chosen as there are easy samples to collect from patients and in 
addition the enzymatic cr assay must have the capability to detect cr concentrations 
regardless of matrix and specifically in serum samples. These patient samples were 
collected by Lahey Hospital and Medical Center in Burlington Massachusetts. These 
samples were collected as de-identified pathologic discard whole blood and serum 
samples.  
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Measure 
 To aid in the development of the enzymatic cr reagent a spectrophotometer was 
used to detect the optimal absorption value and the optimal incubation time. A bench top 
chemistry analyzer was used to conduct detailed evaluation of the parameters selected for 
the assay along with over all evaluation of the assay reagent, and calibration solutions. 
The instruments used are as follows. 
UV-vis spectrometer, Evolution 6000 (Hitachi Ltd, Chiyoda, Japan) with quartz cells for 
optimization of wavelength for assay conditions. The spectrometer was used to determine 
the optimal absorption value for the photophor selected which was the 4-aminoantiparine, 
as well as to determine the optimal incubation time for the assay. Data shown in Figures 
2a and 2b. 
Bench top chemistry analyser, Roche Cobas C311 analyzer (Roche Diagnostics, 
Indianapolis, IN, USA), with programmable channel capability (open channel). Using the 
open channel function for programmability this instrument allowed for the programming 
of the optimized parameters for the enzymatic cr assay and all optimization and final 
analysis was completed using this instrument. 
Reagent 
 To develop a enzymatic cr reagent to use in the analysis of the enzymatic cr assay 
a commercially available assay for crea (Sekisui Diagnostics LLC, Lexington MA) was 
obtained and modified by adding 4-amynoantipyrine and horse radish peroxidase to 
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reagent one of the crea assay. Enzymatic Cr reagent includes the following chemicals and 
enzymes: buffer (pH 7.5) >12000 U/L creatine amidinohydrolase, > 4000 U/L sarcosine 
oxidase, > 2 U/mL horse radish peroxidase, > 0.24 mmol/L N-ethyl-N-sulfopropyl-m-
toluidine, > 0.16mg/mL 4-aminoantipyrine, ascorbate oxidase, stabilizers, surfactants, 
and preservatives.  (22) 
To determine whether the reagent would be satisfactory, a predetermined concentration 
of 4-aminoantipyrin and horse radish peroxidase were added to the Sekisui reagent, for a 
total of 250mL of reagent. Based on the parameters of the Sekisui Creatinine assay, a 
ratio of one part sample to five parts reagent was tested. Total volumes tested were 
1.5mL of reagent and 0.3mL of sample. The sample that was chosen was a 5mg/dL 
concentration of cr in deionized water. The reagent and sample were mixed and allowed 
to incubate for 5 and 30 minutes, at which point absorption spectra was taken using a 
UV-Vis spectrometer (the Evolution 6000) with quartz cell. A blank was taken as well 
which included only the reagent with deionized water (Fig. 2). 
Reference method 
 HPLC analysis was conducted by an outside laboratory (Organix Inc, Woburn 
MA, USA) as an independent check to verify the correct concentrations of our prepared 
standards S1, S2, S3 and S4.  
Isotope Dilution Mass Spectroscopy was conducted to measure cr values in plasma 
samples. 
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Data Process and Statistical Analysis 
 Microsoft excel and Minitab were used for statistical analysis along with figure 
and table generation. 
Calibration Material 
 The cr assay is calibrated using a two point calibration at concentrations 0mg/dL 
and 5mg/dL of cr. The 0mg/dL concentration also serves as a blank measurement for the 
reagent. A 5mg/dL standard was prepared to calibrate the assay. Initially the standard was 
prepared using the gravimetric procedure by dissolving 5mg/dL of cr in deionized water 
at pH 11.0. As part of optimization another procedure was found to be more suitable as it 
showed less variability. This procedure required preparing a high concentration of cr, 
1000mg/dL, and the standard was then prepared by diluting to 5mg/dL. 
As seen in Figure 3, the gravimetric method was conducted by weighing out 44.0mg and 
58.7mg of creatine monohydrate and then dissolving in 1L of deionized water to make a 
3.9mg/dL and 5.2mg/dL cr solution respectively. A 1000mg/dL Cr stock solution was 
prepared by weighing 1.131g of creatine monohydrate and dissolving it in 100mL of 
deionized water. This stock solution was then used to make the two lower concentration 
solutions. The 5.2mg/dL solution was made by adding 52uL of the 1000mg/dL solution 
to 10mL of deionized water and the 3.9mg/dL solution was made by adding 39uL of the 
1000mg/dL solution to 10mL deionized water. 
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Standard material (Control Standards) 
 For the development of standards and calibration materials for the enzymatic cre 
assay samples of known concentration were used to ensure proper function of assay and 
assay calibration. These samples were expected to recover the same value over time as 
they are stable materials and are stored in a refrigerator (2-8C). These materials were 
prepared and values were determined independently so these materials can be used as 
quality control material, HPLC analysis was conducted to assign their value by an outside 
lab, Organix. The target value of cr is 5.2mg/dL. 
When developing calibration standard and procedures these Control Standards were used 
as calibration standards, and other investigational test solutions were tested as samples on 
the cr assay. 
Assay Parameters 
As shown in Table 1, the parameters for this assay are easily programmable for any 
bench top chemistry analyzer that has the capability of an open channel. The required 
sample volume is 30uL, the reagent volume is150uL, an incubation time of 10 minutes 
and a wavelength of 546nm are required to read the final absorbance.  
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Chapter III 
Results 
 
 
 To determine the proper enzymatic cr reagent formulation, the reagent was first 
formulated. Reagent formulation as described in Chapter II was executed by modifying a 
crea reagent purchased by Sekisui, modification was completed by adding HRP and 4-
aminoantipyrine. The enzymatic cr reagent was then tested on a spectrometer to 
determine optimal absorption values and incubation times.  
 To determine the sensitivity of the proposed enzymatic reagent we measured the 
absorbance change of the reagent in the presence of 5mg/dL Cr using UV-Vis 
spectrophotometry. Measurements were taken at various incubation times from 0 to 30 
minutes. The data in Figure 2 shows that the proposed reagent was undergoing a 
chemical change in the presence of Cr which was detected via UV-Vis at absorbance 
peak of 540nm. As shown in Figure 2 the dye selected was the proper dye as the 
interaction with hydrogen peroxide in the presence of horseradish peroxidase caused a 
peak in the spectral scan at 540nm. Furthermore the presence of a peak indicated that the 
concentrations of enzymes and the dye were appropriate. The absorbance data also 
showed that the reaction was fully completed within 10 minutes from the plateau, so the 
incubation time was then set for 10 minutes for the assay. 
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Calibration Solution Development 
 To develop a precise, accurate and stable calibration standard solution, two 
methods of preparation were tested. These calibration solutions were run as samples on 
the Cobas C311 (Roche Diagnostics) using the single reagent enzymatic cr assay after it 
was calibrated with an independent calibration solution. Standards were prepared via 
dilution method and gravimetric method. Gravimetric method was conducted by 
weighing out cr to directly make a 3.9mg/dL and 5.0mg/dL solution, while the dilution 
method was conducted by weighing out cr to first make a 1000mg/dL cr stock solution, 
then diluting that solution to 3.9mg/dL and 5.0mg/dL. As seen in Figure 3 the data shows 
that there is less variability in the preparation of the calibration solution by following the 
dilution method.  
Linearity 
 For proper performance of the assay linearity to substrate must be established and 
determined, if assay is non-linear a mathematical formulation must be established to 
correct to non-linearity. 
 To test for linearity of the assay, concentrations of 0, 1, 2.5, 5,10 and 15mg/dL of 
Cr were prepared via serial dilution. The samples were run on the Cobas C311 using the 
single reagent cr assay after it was calibrated. As seen in Figure 4 the R2 value is > 0.999 
indicating that the assay is linear within the range of 0-15mg/dL cr. 
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Reagent Stability 
 To evaluate the stability of the enzymatic cr assay reagent over its shelf life, 
reagent was prepared and stored under refrigeration (2-4C) and tested after 1, 5, 10, 20, 
30 and 45 days of storage. The stability of the reagent was evaluated by completing a 
three point calibration using 0mg/dL, 3.9mg/dL and 5.2mg/dL of Cr, and correlate the 
absorbance values of each calibration sample versus gravimetric cr concentrations. The 
absorbance value increases as the reagent ages but the linearity of the calibration does not 
change, indicating that the reagent can maintain functionality after 45 days of refrigerated 
storage, giving the assay a shelf life of 45 days (Figure 5). 
Precision and Accuracy 
 To determine the accuracy and precision of the assay, four individual samples 
were prepared and run after three separate calibrations. Samples included crea as well as 
cr to allow for the comparison of the two enzymatic reagent methods which were both 
run simultaneously on the Cobas C311. These Cr results were compared to crea data to 
ensure comparability. As seen in Figure 6a the total variability of recovery for the cr 
assay is minimal and comparable to the crea assay as shown in Figure 6b. As shown in 
Table 2 the crea assay is capable of precision within 1.3% and accuracy within 1.7% and 
0.5% and 1.2% respectively for the enzymatic cr assay, proving that the cr assay is 
comparable to a commercially available crea assay. As can be seen in Figures 7a and 7b, 
day to day, run to run and sample to sample variability are shown for each individual 
sample cr and crea assay respectively.  
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Creatine Assay Performance in Plasma Samples 
 To complete determination of successful enzymatic cr assay clinical samples were 
tested and evaluated using all optimized parameters, reagents (assay reagent and 
calibration samples). 
  To establish the cr assay capability for clinical sample recovery, plasma samples 
of known cr concentration were measured on the Cobas C311 using the cr assay. This 
was done to determine the linearity, accuracy and precision of the method in the clinical 
sample matrix, as opposed to aqueous samples. As can be seen in Figure 8a samples were 
run over a 4 day period and for each day data were used to establish correlation between 
the Isotope Dilution Mass Spectrometry (IDMS) measured values and the cr recovery 
using the cr assay. Data are summarized in Figure 8b and a single formula was calculated 
to show correlation of the two methods. The formula for correlation of Cr assay vs. 
IDMS (to correct the matrix effect) was then used to correct subsequent clinical samples 
as shown in Figure 9 that were run on the Cobas C311 to calculate cr recovery using the 
cr assay 
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Chapter IV 
Discussion 
 
 
 Cr has been investigated since the 1830s and research has revealed its role in the 
proper functioning of the musculatory system (Hunter, 1928; Lundsgaard, E. 1930; 
Balsom 1994). With this knowledge the use of cr as a potential drug for treatment of 
muscular disorders such as Parkinsons, Huntington’s disease and sclerosis, along with 
other musculatory system disorders are subjects of research (Ferrante 2000; Andrew 
1993; Taylor 1995; Bender 2006). The sport nutrition/supplementation market quickly 
realized that cr can be used as a supplement and as such can increase strength, fat free 
mass, and muscle morphology in humans (Cooper 2012). It increases crea storage, which 
in turn increases muscle mass and promotes a faster regeneration of ATP between high 
intensity exercises (Cooper 2012). These improved outcomes will increase performance 
and promote greater training adaptations (Cooper 2012). Although short term use of Cr is 
fairly well understood and considered safe and ethical in the sports world, the perception 
of safety cannot be assumed, that it is safe and ethical especially in long term users from 
diverse population background. To summarize there is an increased need for investigation 
of the impact of cr on potentially beneficial implications as well as long term impact of 
its use as a supplement (Cooper 2012; Yoshizumi 2004).  
 Currently to determine the concentration of cr researchers must rely on methods 
such as HLPC and GC-MS, which are complicated to conduct and require a high level of 
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expertise (Arias 2006; Aebersold 2003; Jonsson 2004; Rawson 2011). Furthermore as 
discussed by Arias et. al. there are also issues with using human serum with such 
techniques that do not allow for accurate measurements due to interference from other 
components that are present in serum (Arias 2006). There is an increasing need for the 
capability of quick analysis of Cr in patient samples to be able to evaluate long term 
impact of supplementation or potential dosage management for use of cr as a drug (Arias 
2006).  
Cr Assay Parameter Optimization 
 An accurate and convenient enzymatic based Cr assay was developed, which is 
easy to use and reports results much quicker than the current methods. The single part 
reagent uses enzymatic conversion of cr with a colorimetric end point detection of 4-
aminoantipyrine at 547nm. The method has been optimized and demonstrated on a bench 
top chemistry analyzer and has a run time of 10 minutes, using only 30uL of sample.  
 The enzymatic reagent is adapted from a commercially available Creatinine assay 
from Sekisui which is then modified by adding 4-aminoantipyrine and horse radish 
peroxidase. To determine whether the reagent would be satisfactory a predetermined 
concertation of 4-aminoantipyrin and horse radish peroxidase were added to the Sekisui 
reagent. Based on the parameters of the Sekisui Creatinine assay and optimization a final 
formulation was reached along with appropriate assay parameters adaptable to a bench 
top chemistry analyzer. 
 Using a Roche Cobas C311 analyzer, which is a bench top chemistry analyzer 
typically used in hospitals for measurements of electrolytes, and metabolites such as crea, 
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the assay and its parameters were evaluated. The assay parameters were programmed into 
the instrument’s open channel, which allows for user programmable assays. The assay 
parameters are simple and easy to program as can be seen in Table 1. For assay 
development the proposed assay was initially calibrated with a 5mg/dL cr in deionized 
water. 
Stability of the Reagent 
 To then study the stability of the regent as it ages a fresh calibration material was 
made and a three point calibration was executed to determine the linearity at multiple test 
points of the reagent shelf life. Testing was executed on the day that the reagent was 
prepared and 5,10,20,30 and 45 days after that with the reagent being stored in a 
refrigerator (2-4 C). As can be seen in Figure 5, all data points show linearity and more 
importantly very similar slopes indicating that the linearity of the assay has not been 
changed over time. This data shows that the cr reagent is stable for at least 45 days when 
stored in the refrigerator.   
Optimize Procedure for Calibration Standards 
 To develop a precise, accurate and stable assay, an equally as accurate and 
reproducible calibration solution is necessary.  To achieve this, two different methods of 
making calibration solutions were evaluated. Initial experiments tested concentrations of 
3.9 and 5.2 mg/dL cr. These two standard concentrations were prepared by two different 
methods. The gravimetric method in which the appropriate concentration of Cr is 
weighed out and dissolved in deionized water. The dilution method, by which a high 
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concertation of cr stock solution is prepared and then diluted down to the final 
concentration was the other method tested. Based on calibration standard preparation 
optimization the dilution method was determined to be the most reproducible and 
accurate preparation method as can be seen in Figure 3.  
Linearity of Assay 
 With optimized assay parameters and calibration standards, we then evaluated the 
linear range of the assay. To do so a high concentration sample of 1000mg/dL cr was 
prepared using creatine monohydrate. This sample was then diluted to 1, 2.5, 5, 10 and 
15mg/dL cr. All samples were tested in triplicate on the Roche Cobas C311 using the Cr 
assay. The data in Figure 3 shows an R2 > 0.999; therefore our assay shows linearity 
within the range of 0-15mg/dL.  
Accuracy and Precision 
 To determine precision and accuracy of the cr assay, three samples from four 
individual cr test solutions were run in triplicate. The test was repeated three times with 
three separate calibrations, giving a total of 27 measurements. Detailed data is presented 
in Figures 6a & 7a. These data were compared to a commercially available Roche crea 
assay to ensure comparability (Figures 6b & 6b). As can be seen in Figure 6a the 
accuracy of the cr assay is comparable to that of the crea assay shown in Figure 6b. This 
experiment summarized replicate to replicate variability, sample to sample variability and 
run to run variability. Also shown in Figures 7a and 7b, no outlier was observed. 
Statistical analysis is shown in Table 2, which indicates that the CV is consistently better 
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for the cr assay as opposed to the crea assay with CVs of 0.28-0.49% and 0.74-1.26% 
respectively. In addition the analysis indicated better accuracy with the cr assay ranging 
from 0.4-1.2% as compared to the crea assay ranging from 0.8-1.7%. The data also show 
that there is no interference from crea as all solutions recover very close to their 
gravimetric values with and without the presence of crea. Samples S1, S3 and S4 are 
mixtures of both crea and cr and the presence of these chemicals together does not impact 
the recovery of the cr assay, as seen in Table 2. Furthermore, the data shown in table 2 
indicated that the cr assay gives both better precision and accuracy than the commercially 
available crea assay. This could be explained by the volume ratio of sample to assay 
reagent as the commercially available crea assay has a ratio of 1:32 in comparison to that 
of the cr assay of 1:5. The higher sample volume that the cr assay has could explain the 
improvement in the accuracy and precision over the commercially available crea assay.   
Recovery in Clinical Samples 
 Performance of the cr assay on the Cobas C311 in plasma samples was evaluated 
by testing plasma samples with cr values determined by IDMS, as seen in Figure 8. Three 
levels of plasma samples were tested at 0.5mg/dl, 1.8mg/dL and 4.5mg/dL. All samples 
were tested in duplicates over four separate days under four separate calibrations. The 
data was correlated against the IDMS measured values as can be seen in Figures 8a and 
b, showed good linearity R2 > 0.99 for samples between 0.5-4.5mg/dL cr.  These data 
show that regardless of the sample matrix the cr assay developed on the Cobas C311 has 
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good linearity (R2 > 0.99).  The bias at these three levels and the CV from run to run are 
well within our original goals, as can be seen in Table 3 and Table 4. 
 There was a bias of +0.2479 as can be seen in Figure 8b against the IDMS which 
is likely due to plasma sample matrix effect versus aqueous calibration. The effect can be 
corrected if sample measurements are normalized against IDMS serum samples. As can 
be seen in Figure 9 clinical samples that were tested on the Cobas C311 using the cr 
assay and then normalized versus IDMS fall within the described clinical ranges (0.2-1.7 
mg/dL +/- 0.3) with some high samples that were spiked to increase the cr concentration. 
Clinical samples tested using the enzymatic Cr show recovery of 0.26 -1.26 mg/dL +/- 
0.24 (excluding the spiked samples), showing that the cr assay developed is capable of 
measuring cr in clinical samples (Straseski 2011). 
 Based on the data presented, a enzymatic cr assay that can be used to measure 
clinical samples on a bench top chemistry analyzer was developed and successfully met 
all of the requirements that we set out in Table 4. The assay is a single part reagent that 
uses enzymatic conversion of cr with colorimetric end point detection of 4-
aminoantipyrine at 547nm. The assay uses a small sample size of 30uL, and takes 10 
minutes (Table 2 and 4). Furthermore the enzymatic cr assay has proven linearity from 0-
15mg/dL, accuracy within 2%, run to run CV from 1.6-5.3% for clinical samples and 
finally sample to sample CV of less than 0.5%. This assay can easily be adapted for any 
bench top chemistry analyzer that has the capability of a programmable channel, and can 
analyze clinical samples with accuracy, precision and reproducibility. In comparison to 
other methods of cr detection such as HPLC and GS/MS the enzymatic cr assay has less 
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interference from sample matrix and the accuracy and precision is comparable to both 
methods, with the enzymatic cr assay having precision and accuracy within 2%, recovery 
of 0.5% as compared to HPLC which has better precision and accuracy which is as low 
as 0.5% but has many interference issues from samples matrix, GS/MS has similar issues 
and recovery. This enzymatic cr assay could have future application for the potential 
beneficial implication of cr, as well as investigation on the long term impact of cr 
supplementation of healthy individuals.   
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Appendix 1. Tables 
Table 1. Cr assay parameters programmed on the open channel option on the Roche    
 Cobas C311. 
Creatine Assay on Roche C311 
Parameter 
Sample Volume (uL) 30 
Reagent Volume (uL) 150 
Assay type 1-point 
Time (minutes) 10 
Wavelength (nm) 546 
Absorbance Limit  Increase 
Measurement taken (cycle) 57 
Reagent Used IL-Cr_Sek 
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Table 2: Results of Precision study of new cr assay vs commercial Roche crea assay on 
Roche Cobas C311 
Sample ID S1 S2 S3 S4 
Analyte Cr Crea Cr Crea Cr Crea Cr Crea 
Gravimetric Value 
(mg/dL) 
5.2 3.0 3.8 0.0 5.0 2.9 3.6 1.0 
Average Recovery 
(mg/dL)( 
5.18 2.97 3.77 0.14 5.06 2.85 3.63 1.08 
SD 0.01 0.02 0.02 0.01 0.02 0.04 0.01 0.01 
Precision (%CV) 0.28 0.74 0.44 n/a 0.49 1.26 0.41 1.00 
Inaccuracy (%) 0.4 1.0 0.8 n/a 1.2 1.7 0.8 8.0 
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Table 3: Summary data of Cr recovery from plasma samples 
Plasma Samples Level1 Level2 Level3 
IDMS Value 
(mg/dL) 
0.5 1.8 4.5 
Average Cr assay  recovery 
(mg/dL) 
0.7 1.7 3.9 
SD 0.035 0.029 0.062 
CV run to run 5.3 1.7 1.6 
CV sample to sample 0.5 0.4 0.2 
Inaccuracy (%) +30 -8 -13.0 
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Table 4: Summary of Goals and performance for Cr assay 
Goal Achieved 
Performance 
Reference Pass/Fail 
Sample and reagent volume < 
300uL 
180uL Table 1 Pass 
Incubation time < 20 minutes 10 minutes Table 1 Pass 
Linarity 0-15mg/dL 0-15mg/dL Figure 4 Pass 
Accuracy within 2% 1.20% Table 2 Pass 
Run to run CV < 2% 5.3%, 1.6% and 
1.7% 
Table 3 Pass 
Sample to sample CV < 0.5% 0.5%, 0.4% and 
0.2% 
Table 3 Pass 
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Appendix 2. Figures 
 
Figure 1. Enzymatic Cascade from creatinine to hydrogen peroxide. 
Pictorial description of the change that occurs for the Crea enzymatic reaction for the 
conversion of creatinine to hydrogen peroxide.  Which allows for the interaction of 
hydrogen peroxide with 4-aminoantipyrine to give a colorimetric change allowing for the 
detection of Crea concentration.  
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 Figure 2a. UV Absorption spectra of enzymatic cr reagent. 
Uv-vis spectrometer: Evolution 6000 with quartz cells.  Sekisui Reagent  RI modified 
with 2U/mL HRP and 16 mg/dL 4-AMP, 2.5 mL.  Sample: 5 mg/dL Cr solution, 0.5 mL.  
Blank: DI water. Absorbance collected at 0, 5, 10, 20, and 30 minutes of incubation time.  
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Figure 2b.  Absorbance versus time profile for enzymatic single cr assay reagent. 
Uv-vis spectrometer: Evolution 6000 with quartz cells.  Sekisui Reagent  RI modified 
with 2U/mL HRP and 16 mg/dL 4-AMP, 2.5 mL.  Sample: 5 mg/dL Cr solution, 0.5 mL.  
Blank: DI water. Absorbance collected at 0, 5, 10, 20, and 30 minutes of incubation time 
at 547nm. 
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Figure 3.  Comparison of two calibration standard prep methods. 
Two different concentrations, 3.9mg/dL and 5.2mg/dL were tested by both methods.  
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Figure 4.  Linearity of Cr assay. 
Total of  6 samples at gravimetric values of 0, 1.5, 2.5, 5, 10 and 15mg/dL cr were run in 
replicated of five on the Roche Cobas C311 using the single reagent cr assay. 
Gravimetric Values of Cr solution against the reported cr values by the cr assay adapted 
to the Cobas C311.  
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Figure 5. Study of single Reagent shelf life stability. 
Scatterplot for cr assay linearity of fresh standards in miliabsorbance over a period of 45 
days of reagent shelf life. Each data point represent duplicated samples of each 
concentration point of each calibration. 
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Figure 6a. Summary of all variability for Cr assay. 
Summary of all variability on four different test solutions for Cr results by cr assay tested 
on the Cobas C311. The average along with the 95% confidence interval showed the 
overall variability of the assay. Source of variability includes calibration to calibration, 
and sample imprecision. Data point representing each sample includes the average and 
95% confidence interval of a total of 27 measurements. Test were completed on three 
different days, on each day a fresh calibration using fresh calibration standards was 
conducted, three different preparations of Samples 1- 4 were made and tested in 
triplicated using the cr assay on the Roche Cobas C311.  
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Figure 6b. Summary of all variability for Crea precision study  
Summary of all variability on four different test solutions for Crea results by Roche crea 
assay tested on the Cobas C311. The average, shown with the 95% confidence interval 
showed the overall variability of the assay. Source of variability includes calibration to 
calibration, and sample imprecision. Data point representing each sample includes the 
average and 95% confidence interval of a total of 27 measurements. Tests were 
completed on three different days. On each test day a fresh calibration solution was 
prepared and used to calibrate the instrument, this was repeated twice. Samples 1- 4 were 
made and tested in triplicated using the crea assay on the Roche Cobas C311.  
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Figure 7a.  Day to Day, Run to run and sample to sample variability of Cr assay precision 
study. 
All individual data points are presented to show the overall change when presented with 
different variables. Variability of run to run, sample to sample and replicate to replicate 
for Cr recovery on Roche C311 Cr assay.  These are all individual measurements shown 
summarized in Fig 6a. 
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Figure 7b. Day to Day, Run to run and sample to sample variability of Crea assay. 
All individual data points are presented to show the overall change in value when 
presented with different variables. Variability of run to run, sample to sample and 
replicate to replicate for Crea on Roche C311crea assay. These are all individual data 
points shown summarized in Fig 6b. 
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Figure 8a. Cr recovery from plasma samples (enzymatic assay on Cobas C311 vs IDMS) 
Plasma samples were tested on the Cobas C311 to determine cr recovery. Data was 
correlated to the Isotope Dilution Mass Spectrometry (IDMS) measured values to 
determine the correlation. Data were collected in duplicate over four different days to 
account for run to run variations. 
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Figure 8b. Average Cr recovery from plasma samples (enzymatic assay on Cobas C311 
vs IDMS) 
Using all data collected in duplicate over a period of four days a single formula was 
calculated to determine the bias of the two methods - the cr assay on the Cobas C311 vs 
IDMS. 
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Figure 9. Distribution of cr values from 60 clinical patient samples run on the Cobas 
 C311 with normalization to IDMS samples. 
Dot plot of Clinical sample recovery using the cr assay after correction of bias the 
calculated formula from IDMS samples. 
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Appendix 3. Raw Data 
Absorbance Data 
nm  A  nm  A  nm  A  nm  A 
400  0.088  400  0.1  400 0.235 400 0.316 
401  0.086  401  0.096  401 0.23 401 0.311 
402  0.081  402  0.093  402 0.226 402 0.307 
403  0.081  403  0.093  403 0.225 403 0.304 
404  0.078  404  0.089  404 0.223 404 0.301 
405  0.076  405  0.087  405 0.219 405 0.296 
406  0.073  406  0.084  406 0.214 406 0.292 
407  0.075  407  0.084  407 0.214 407 0.292 
408  0.069  408  0.08  408 0.208 408 0.283 
409  0.069  409  0.08  409 0.206 409 0.281 
410  0.066  410  0.08  410 0.205 410 0.278 
411  0.066  411  0.078  411 0.201 411 0.274 
412  0.063  412  0.073  412 0.196 412 0.269 
413  0.064  413  0.075  413 0.195 413 0.267 
414  0.062  414  0.073  414 0.192 414 0.265 
415  0.061  415  0.072  415 0.19 415 0.261 
416  0.06  416  0.071  416 0.188 416 0.258 
417  0.058  417  0.068  417 0.185 417 0.253 
418  0.058  418  0.07  418 0.184 418 0.252 
419  0.058  419  0.07  419 0.183 419 0.249 
420  0.056  420  0.067  420 0.18 420 0.246 
421  0.056  421  0.068  421 0.178 421 0.244 
422  0.056  422  0.068  422 0.178 422 0.243 
423  0.057  423  0.067  423 0.175 423 0.238 
424  0.054  424  0.066  424 0.173 424 0.237 
425  0.056  425  0.067  425 0.174 425 0.236 
426  0.054  426  0.065  426 0.172 426 0.234 
427  0.052  427  0.063  427 0.168 427 0.231 
428  0.055  428  0.066  428 0.169 428 0.23 
429  0.052  429  0.063  429 0.166 429 0.227 
430  0.055  430  0.064  430 0.167 430 0.228 
431  0.053  431  0.063  431 0.164 431 0.225 
432  0.051  432  0.063  432 0.162 432 0.222 
433  0.054  433  0.062  433 0.161 433 0.219 
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434  0.055  434  0.066  434 0.162 434 0.22 
435  0.052  435  0.062  435 0.157 435 0.215 
436  0.054  436  0.063  436 0.158 436 0.215 
437  0.053  437  0.063  437 0.156 437 0.21 
438  0.054  438  0.064  438 0.154 438 0.209 
439  0.054  439  0.064  439 0.154 439 0.206 
440  0.054  440  0.064  440 0.152 440 0.204 
441  0.055  441  0.065  441 0.15 441 0.201 
442  0.054  442  0.064  442 0.146 442 0.197 
443  0.057  443  0.066  443 0.147 443 0.196 
444  0.057  444  0.065  444 0.145 444 0.191 
445  0.057  445  0.067  445 0.145 445 0.191 
446  0.058  446  0.067  446 0.142 446 0.186 
447  0.058  447  0.067  447 0.141 447 0.184 
448  0.059  448  0.068  448 0.141 448 0.184 
449  0.059  449  0.068  449 0.139 449 0.182 
450  0.059  450  0.068  450 0.138 450 0.179 
451  0.059  451  0.068  451 0.137 451 0.179 
452  0.059  452  0.068  452 0.137 452 0.176 
453  0.06  453  0.069  453 0.136 453 0.178 
454  0.059  454  0.069  454 0.135 454 0.175 
455  0.06  455  0.069  455 0.135 455 0.173 
456  0.059  456  0.069  456 0.135 456 0.175 
457  0.058  457  0.069  457 0.134 457 0.173 
458  0.058  458  0.068  458 0.135 458 0.175 
459  0.056  459  0.066  459 0.134 459 0.174 
460  0.057  460  0.067  460 0.136 460 0.175 
461  0.058  461  0.066  461 0.136 461 0.177 
462  0.056  462  0.067  462 0.137 462 0.178 
463  0.056  463  0.067  463 0.139 463 0.182 
464  0.055  464  0.066  464 0.139 464 0.182 
465  0.054  465  0.064  465 0.14 465 0.184 
466  0.054  466  0.064  466 0.141 466 0.186 
467  0.055  467  0.064  467 0.143 467 0.192 
468  0.054  468  0.065  468 0.147 468 0.195 
469  0.054  469  0.065  469 0.149 469 0.199 
470  0.053  470  0.063  470 0.152 470 0.203 
471  0.054  471  0.064  471 0.156 471 0.207 
472  0.054  472  0.064  472 0.159 472 0.213 
473  0.053  473  0.064  473 0.162 473 0.216 
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474  0.051  474  0.062  474 0.163 474 0.221 
475  0.052  475  0.063  475 0.166 475 0.226 
476  0.05  476  0.062  476 0.17 476 0.232 
477  0.052  477  0.064  477 0.175 477 0.239 
478  0.05  478  0.063  478 0.177 478 0.244 
479  0.05  479  0.063  479 0.182 479 0.25 
480  0.05  480  0.063  480 0.185 480 0.255 
481  0.048  481  0.063  481 0.189 481 0.261 
482  0.047  482  0.06  482 0.193 482 0.268 
483  0.047  483  0.064  483 0.198 483 0.276 
484  0.047  484  0.061  484 0.204 484 0.283 
485  0.047  485  0.06  485 0.205 485 0.288 
486  0.044  486  0.059  486 0.211 486 0.295 
487  0.042  487  0.058  487 0.214 487 0.301 
488  0.042  488  0.059  488 0.219 488 0.31 
489  0.042  489  0.058  489 0.223 489 0.317 
490  0.038  490  0.056  490 0.227 490 0.323 
491  0.037  491  0.056  491 0.231 491 0.33 
492  0.036  492  0.054  492 0.235 492 0.337 
493  0.033  493  0.052  493 0.239 493 0.344 
494  0.032  494  0.05  494 0.243 494 0.352 
495  0.031  495  0.051  495 0.247 495 0.361 
496  0.027  496  0.049  496 0.253 496 0.368 
497  0.025  497  0.046  497 0.256 497 0.375 
498  0.025  498  0.046  498 0.263 498 0.387 
499  0.023  499  0.045  499 0.266 499 0.393 
500  0.021  500  0.044  500 0.272 500 0.402 
501  0.02  501  0.043  501 0.278 501 0.41 
502  0.018  502  0.043  502 0.283 502 0.419 
503  0.017  503  0.043  503 0.289 503 0.429 
504  0.016  504  0.043  504 0.296 504 0.438 
505  0.015  505  0.041  505 0.301 505 0.448 
506  0.014  506  0.039  506 0.305 506 0.458 
507  0.012  507  0.04  507 0.311 507 0.467 
508  0.011  508  0.039  508 0.319 508 0.476 
509  0.01  509  0.039  509 0.324 509 0.486 
510  0.011  510  0.039  510 0.33 510 0.495 
511  0.01  511  0.038  511 0.337 511 0.505 
512  0.009  512  0.039  512 0.344 512 0.514 
513  0.009  513  0.039  513 0.35 513 0.525 
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514  0.007  514  0.038  514 0.355 514 0.533 
515  0.009  515  0.041  515 0.361 515 0.543 
516  0.007  516  0.04  516 0.368 516 0.551 
517  0.007  517  0.039  517 0.373 517 0.56 
518  0.007  518  0.04  518 0.379 518 0.569 
519  0.007  519  0.04  519 0.385 519 0.578 
520  0.005  520  0.04  520 0.391 520 0.587 
521  0.005  521  0.04  521 0.396 521 0.595 
522  0.004  522  0.04  522 0.401 522 0.602 
523  0.004  523  0.041  523 0.406 523 0.611 
524  0.005  524  0.042  524 0.413 524 0.619 
525  0.006  525  0.042  525 0.418 525 0.626 
526  0.004  526  0.041  526 0.42 526 0.633 
527  0.004  527  0.044  527 0.426 527 0.642 
528  0.005  528  0.043  528 0.431 528 0.648 
529  0.003  529  0.044  529 0.435 529 0.654 
530  0.002  530  0.042  530 0.438 530 0.659 
531  0.005  531  0.044  531 0.444 531 0.666 
532  0.003  532  0.045  532 0.448 532 0.674 
533  0.006  533  0.047  533 0.453 533 0.679 
534  0.005  534  0.047  534 0.458 534 0.686 
535  0.002  535  0.045  535 0.46 535 0.691 
536  0.003  536  0.046  536 0.465 536 0.697 
537  0.003  537  0.047  537 0.468 537 0.701 
538  0.002  538  0.046  538 0.471 538 0.706 
539  0.003  539  0.048  539 0.473 539 0.711 
540  0.003  540  0.048  540 0.478 540 0.717 
541  0.002  541  0.048  541 0.482 541 0.72 
542  0.003  542  0.047  542 0.484 542 0.724 
543  0.004  543  0.048  543 0.486 543 0.728 
544  0.002  544  0.049  544 0.489 544 0.732 
545  0.003  545  0.049  545 0.492 545 0.736 
546  0.002  546  0.049  546 0.492 546 0.739 
547  0.003  547  0.05  547 0.495 547 0.74 
548  0.003  548  0.049  548 0.497 548 0.744 
549  0.002  549  0.049  549 0.497 549 0.743 
550  0.004  550  0.051  550 0.499 550 0.746 
551  0.003  551  0.05  551 0.498 551 0.747 
552  0.002  552  0.05  552 0.497 552 0.744 
553  0.003  553  0.051  553 0.496 553 0.743 
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554  0.001  554  0.05  554 0.496 554 0.741 
555  0.001  555  0.051  555 0.494 555 0.738 
556  0.003  556  0.051  556 0.493 556 0.737 
557  0.001  557  0.049  557 0.49 557 0.732 
558  0.001  558  0.049  558 0.487 558 0.727 
559  0.002  559  0.05  559 0.484 559 0.723 
560  0.002  560  0.05  560 0.481 560 0.717 
561  0.001  561  0.048  561 0.474 561 0.71 
562  0.003  562  0.049  562 0.472 562 0.704 
563  0.002  563  0.05  563 0.467 563 0.697 
564  0.002  564  0.048  564 0.46 564 0.688 
565  0  565  0.047  565 0.455 565 0.678 
566  0.002  566  0.046  566 0.449 566 0.669 
567  0.002  567  0.047  567 0.446 567 0.663 
568  0  568  0.046  568 0.438 568 0.653 
569  0.001  569  0.046  569 0.43 569 0.643 
570  0.001  570  0.045  570 0.426 570 0.633 
571  0.001  571  0.044  571 0.419 571 0.622 
572  0.003  572  0.045  572 0.413 572 0.614 
573  0  573  0.042  573 0.405 573 0.602 
574  0.001  574  0.043  574 0.398 574 0.591 
575  0.001  575  0.043  575 0.39 575 0.582 
576  0.001  576  0.043  576 0.385 576 0.571 
577  0.002  577  0.042  577 0.38 577 0.563 
578  0.002  578  0.041  578 0.372 578 0.552 
579  0  579  0.04  579 0.365 579 0.541 
580  0.003  580  0.041  580 0.359 580 0.534 
581  0.002  581  0.039  581 0.353 581 0.522 
582  0.001  582  0.04  582 0.347 582 0.514 
583  0.001  583  0.039  583 0.34 583 0.505 
584  0.002  584  0.037  584 0.335 584 0.494 
585  0.004  585  0.039  585 0.329 585 0.487 
586  0.002  586  0.037  586 0.324 586 0.478 
587  0.002  587  0.035  587 0.317 587 0.469 
588  0.002  588  0.037  588 0.312 588 0.462 
589  0.001  589  0.036  589 0.308 589 0.453 
590  0.001  590  0.035  590 0.303 590 0.447 
591  0  591  0.035  591 0.297 591 0.439 
592  0.002  592  0.036  592 0.294 592 0.432 
593  0.001  593  0.034  593 0.288 593 0.424 
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594  0.003  594  0.034  594 0.283 594 0.417 
595  0.001  595  0.032  595 0.278 595 0.409 
596  0.001  596  0.033  596 0.274 596 0.403 
Calibration Standard Method Development 
S_ID Value Run SampleState 
5_1                    4.860 1 1 gravimetric 
5_1                    4.842 1 1 gravimetric 
5_1                    4.854 1 1 gravimetric 
5_1                    4.835 1 1 gravimetric 
5_1                    4.851 1 1 gravimetric 
5_2                    5.169 1 2 gravimetric 
5_2                    5.173 1 2 gravimetric 
5_2                    5.164 1 2 gravimetric 
5_2                    5.186 1 2 gravimetric 
5_2                    5.172 1 2 gravimetric 
5_3                    4.795 1 3 gravimetric 
5_3                    4.778 1 3 gravimetric 
5_3                    4.786 1 3 gravimetric 
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5_3                    4.791 1 3 gravimetric 
5_3                    4.788 1 3 gravimetric 
5_1                    4.881 2 1 gravimetric 
5_1                    4.894 2 1 gravimetric 
5_1                    4.886 2 1 gravimetric 
5_1                    4.901 2 1 gravimetric 
5_1                    4.901 2 1 gravimetric 
5_2                    5.146 2 2 gravimetric 
5_2                    5.140 2 2 gravimetric 
5_2                    5.149 2 2 gravimetric 
5_2                    5.138 2 2 gravimetric 
5_2                    5.137 2 2 gravimetric 
5_3                    4.777 2 3 gravimetric 
5_3                    4.784 2 3 gravimetric 
5_3                    4.793 2 3 gravimetric 
5_3                    4.779 2 3 gravimetric 
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5_3                    4.780 2 3 gravimetric 
5_1 4.870 3 1 gravimetric 
5_1 4.855 3 1 gravimetric 
5_1 4.855 3 1 gravimetric 
5_1 4.860 3 1 gravimetric 
5_1 4.870 3 1 gravimetric 
5_2 5.100 3 2 gravimetric 
5_2 5.121 3 2 gravimetric 
5_2 5.111 3 2 gravimetric 
5_2 5.114 3 2 gravimetric 
5_2 5.108 3 2 gravimetric 
5_3 4.769 3 3 gravimetric 
5_3 4.754 3 3 gravimetric 
5_3 4.767 3 3 gravimetric 
5_3 4.764 3 3 gravimetric 
5_3 4.776 3 3 gravimetric 
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5 4.896 1 1 dilution 
5 4.907 1 1 dilution 
5 4.908 1 1 dilution 
5 4.901 1 1 dilution 
5 4.899 1 1 dilution 
5 4.899 1 2 dilution 
5 4.896 1 2 dilution 
5 4.911 1 2 dilution 
5 4.889 1 2 dilution 
5 4.908 1 2 dilution 
5 4.868 1 3 dilution 
5 4.901 1 3 dilution 
5 4.879 1 3 dilution 
5 4.898 1 3 dilution 
5 4.873 1 3 dilution 
5 4.918 2 1 dilution 
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5 4.906 2 1 dilution 
5 4.918 2 1 dilution 
5 4.902 2 1 dilution 
5 4.926 2 1 dilution 
5 4.905 2 2 dilution 
5 4.910 2 2 dilution 
5 4.914 2 2 dilution 
5 4.924 2 2 dilution 
5 4.904 2 2 dilution 
5 4.896 2 3 dilution 
5 4.894 2 3 dilution 
5 4.905 2 3 dilution 
5 4.906 2 3 dilution 
5 4.901 2 3 dilution 
5 4.907 3 1 dilution 
5 4.904 3 1 dilution 
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5 4.907 3 1 dilution 
5 4.894 3 1 dilution 
5 4.899 3 1 dilution 
5 4.894 3 2 dilution 
5 4.902 3 2 dilution 
5 4.882 3 2 dilution 
5 4.903 3 2 dilution 
5 4.893 3 2 dilution 
5 4.884 3 3 dilution 
5 4.876 3 3 dilution 
5 4.894 3 3 dilution 
5 4.880 3 3 dilution 
5 4.894 3 3 dilution 
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Linearity Data 
S_ID  Value  V_Unit 
0  0.012  mg/dL  
0  0.009  mg/dL  
0  0.011  mg/dL  
1  1.006  mg/dL  
1  1.007  mg/dL  
1  1.006  mg/dL  
2.5  2.506  mg/dL  
2.5  2.513  mg/dL  
2.5  2.517  mg/dL  
5  5.012  mg/dL  
5  5.006  mg/dL  
5  5.009  mg/dL  
10  9.933  mg/dL  
10  9.955  mg/dL  
10  9.948  mg/dL  
15  14.9615  mg/dL  
15  14.964  mg/dL  
15  14.9605  mg/dL  
 
Reagent Shelf Life Data 
Cr_Cal Cnc Bad_Cal Cal_1 Cal_2 Cal_3 Cal_4 Cal_New_reag
 Average for all Cals 
0.0 1128 2571 2106 1617 1310 260 1498.67 
0.0 1128 2564 2077 1617 1306 247 1489.83 
3.9 5645 6921 6482 6022 5778 5451 6049.83 
3.9 5634 6902 6461 6019 5771 5431 6036.33 
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5.2 7112 8363 7948 7497 7237 7214 7561.83 
5.2 7113 8355 7921 7489 7232 7213 7553.83 
 
Crea and Cr assay comparison 
S_ID Cr_mg/dL Crea_mg/dL Run SampleReplicate 
wca                    5.202 3.00 1 1 1 
wca                    5.207 2.97 1 1 2 
wca                    5.195 2.95 1 1 3 
wca                    5.198 2.98 1 2 1 
wca                    5.202 2.96 1 2 2 
wca                    5.200 2.96 1 2 3 
wca                    5.168 2.98 1 3 1 
wca                    5.185 2.97 1 3 2 
wca                    5.193 3.03 1 3 3 
wca                    5.170 2.98 2 1 1 
wca                    5.168 2.98 2 1 2 
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wca                    5.185 2.97 2 1 3 
wca                    5.170 2.97 2 2 1 
wca                    5.173 2.93 2 2 2 
wca                    5.166 2.94 2 2 3 
wca                    5.153 2.99 2 3 1 
wca                    5.161 2.99 2 3 2 
wca                    5.161 2.94 2 3 3 
wca                    5.168 2.97 3 1 1 
wca                    5.175 3.01 3 1 2 
wca                    5.171 2.99 3 1 3 
wca                    5.185 2.95 3 2 1 
wca                    5.183 2.97 3 2 2 
wca                    5.185 2.99 3 2 3 
wca                    5.175 2.99 3 3 1 
wca                    5.166 2.99 3 3 2 
wca                    5.178 2.97 3 3 3 
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Cal A                      5.084 2.90 1 1 1 
Cal A                      5.084 2.88 1 1 2 
Cal A                      5.069 2.90 1 1 3 
Cal A                      5.079 2.91 1 2 1 
Cal A                      5.074 2.86 1 2 2 
Cal A                      5.084 2.91 1 2 3 
Cal A                      5.106 2.86 1 3 1 
Cal A                      5.104 2.86 1 3 2 
Cal A                      5.086 2.91 1 3 3 
Cal A                      5.060 2.78 2 1 1 
Cal A                      5.052 2.87 2 1 2 
Cal A                      5.040 2.85 2 1 3 
Cal A                      5.050 2.81 2 2 1 
Cal A                      5.072 2.80 2 2 2 
Cal A                      5.035 2.87 2 2 3 
Cal A                      5.023 2.82 2 3 1 
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Cal A                      5.020 2.85 2 3 2 
Cal A                      5.037 2.87 2 3 3 
Cal A                      5.038 2.84 3 1 1 
Cal A                      5.040 2.82 3 1 2 
Cal A                      5.023 2.82 3 1 3 
Cal A                      5.038 2.82 3 2 1 
Cal A                      5.048 2.86 3 2 2 
Cal A                      5.045 2.82 3 2 3 
Cal A                      5.045 2.82 3 3 1 
Cal A                      5.040 2.86 3 3 2 
Cal A                      5.038 2.88 3 3 3 
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IDMS Sample Data 
IDMS 
Assignment 
Cr 
Recovery 
0.508  0.687803 
0.508  0.689788 
1.805  1.680303 
1.805  1.650528 
4.583  3.857848 
4.583  3.824103 
0.508  0.680543 
0.508  0.685561 
1.805  1.698345 
1.805  1.707379 
4.583  4.036079 
4.583  4.025038 
0.508  0.685758 
0.508  0.67371 
1.805  1.679756 
1.805  1.702849 
4.583  3.859524 
4.583  3.911734 
4.583  4.566254 
4.583  4.566254 
1.805  1.798405 
1.805  1.798405 
0.508  0.506144 
0.508  0.506144 
 
Clinical Sample Data 
Data SampleCr(mg/L) Calc_Cr(mg/dL) 
12/9/2015 c1                     0.600 0.44198 
12/9/2015 c1                     0.599 0.44073 
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12/9/2015 c2                     0.637 0.48822 
12/9/2015 c2                     0.633 0.48322 
12/9/2015 c3                     0.460 0.26701 
12/9/2015 c3                     0.455 0.26076 
12/9/2015 c4                     0.740 0.61695 
12/9/2015 c4                     0.747 0.62570 
12/9/2015 c5                     0.656 0.51197 
12/9/2015 c5                     0.671 0.53072 
12/9/2015 c6                     0.746 0.62445 
12/9/2015 c6                     0.758 0.63945 
12/9/2015 c7                     0.636 0.48697 
12/9/2015 c7                     0.652 0.50697 
12/14/2015 D1                     0.494 0.30950 
12/14/2015 D1                     0.493 0.30825 
12/14/2015 D2                     0.672 0.53197 
12/14/2015 D2                     0.698 0.56446 
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12/14/2015 D3                     0.985 0.92315 
12/14/2015 D3                     0.968 0.90191 
12/14/2015 D4                     1.255 1.26060 
12/14/2015 D4                     1.232 1.23185 
12/14/2015 D5                     0.777 0.66319 
12/14/2015 D5                     0.784 0.67194 
12/14/2015 D6                     0.917 0.83817 
12/14/2015 D6                     0.916 0.83692 
12/14/2015 D7                     0.906 0.82442 
12/14/2015 D7                     0.900 0.81692 
12/14/2015 D8                     0.637 0.48822 
12/14/2015 D8                     0.666 0.52447 
12/14/2015 WB                     0.607 0.45073 
12/14/2015 WB                     0.615 0.46073 
12/10/2015 Creat Lvl 1   0.686 0.54946 
12/10/2015 Creat Lvl 1   0.663 0.52072 
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12/10/2015 Creat Lvl 2   0.777 0.66319 
12/10/2015 Creat Lvl 2   0.725 0.59820 
12/10/2015 Creat Lvl 3   0.647 0.50072 
12/10/2015 Creat Lvl 3   0.692 0.55696 
12/10/2015 Creat Lvl 4   0.692 0.55696 
12/10/2015 Creat Lvl 4   0.715 0.58571 
12/10/2015 Creat Lvl 5   0.715 0.58571 
12/10/2015 Creat Lvl 5   0.721 0.59321 
12/10/2015 Creat Lvl 6   0.769 0.65320 
12/10/2015 Creat Lvl 6   0.757 0.63820 
12/16/2015 X1                     0.856 0.76193 
12/16/2015 X1                     0.873 0.78318 
12/16/2015 X2                     0.468 0.27701 
12/16/2015 X2                     * -0.30790 
12/16/2015 X3                     0.469 0.27826 
12/16/2015 X3                     0.474 0.28451 
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12/16/2015 X4                     0.767 0.65070 
12/16/2015 X4                     0.765 0.64820 
12/16/2015 X5                     5.216 6.21106 
12/16/2015 X5                     5.189 6.17731 
12/16/2015 X6                     4.215 4.96001 
12/16/2015 X6                     4.212 4.95626 
12/16/2015 X7                     5.352 6.38103 
12/16/2015 X7                     5.358 6.38853 
12/16/2015 X8                     4.258 5.01375 
12/16/2015 X8                     4.240 4.99125 
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